Laurie McMahon
Family Medicine · Vail, AZNPI 1992343362
Payments from drug & device makers
Across 81 payments — averaging $40.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$350
- AbbVie$342
- Johnson & Johnson$143
- Actelion Pharmaceuticals US, Inc.$129
- Genentech USA, Inc.$125
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,264100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $1,118 |
| GSK | 12 | $350 |
| AbbVie | 8 | $342 |
| Johnson & Johnson | 1 | $143 |
| Actelion Pharmaceuticals US, Inc. | 1 | $129 |
| Genentech USA, Inc. | 1 | $125 |
| Lilly USA, LLC | 6 | $124 |
| Teva Pharmaceuticals USA, Inc. | 1 | $121 |
| Cranial Technologies, Inc | 8 | $115 |
| Insulet Corporation | 1 | $106 |
| Boehringer Ingelheim | 1 | $100 |
| Cvrx, Inc. | 1 | $98 |
| Medtronic | 1 | $69 |
| Nestle Healthcare Nutrition Inc. | 3 | $50 |
| Biohaven Pharmaceuticals, Inc. | 3 | $41 |
| Exact Sciences | 2 | $38 |
| Novo Nordisk | 2 | $31 |
| Pfizer | 2 | $30 |
| Merck | 2 | $28 |
| Gilead | 1 | $21 |
| Amgen | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $14 |
| Dexcom, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,264 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 11 | $17,617 |
| OzempicSemaglutide | 14 | $13,705 |
| MounjaroTirzepatide | 11 | $10,738 |
| DuleraMometasone/Formoterol | 12 | $4,141 |
| Omeprazole | 43 | $550 |
| Levothyroxine Sodium | 54 | $499 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $484 |
| Metoprolol Succinate | 26 | $401 |
| Lisinopril | 52 | $365 |
| Losartan Potassium | 38 | $326 |
| Atorvastatin Calcium | 34 | $296 |
| Duloxetine Hcl | 13 | $290 |
| Gabapentin | 17 | $249 |
| Famotidine | 17 | $226 |
| Rosuvastatin Calcium | 33 | $196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,118 | $17,61711 claims |
| Novo NordiskOzempic | $31 | $13,70514 claims |
| Lilly USA, LLCMounjaro | $124 | $10,73811 claims |
| MerckDulera | $28 | $4,14112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Vail
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
- Corey AndersonMesa$21.5M
- Dena PetersenTucson$14.7M
- Gerald ShockeyMesa$12.3M
- Brock MerrittPhoenix$8.4M
- John McGettiganTucson$8.3M
- Neil ShethChandler$6.7M
- Joseph LilloScottsdale$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.